Barclays
http://www.barclays.com/Barclays plc is a global financial services provider engaged in retail and commercial banking, credit cards, investment banking, wealth management and investment management services. It has an extensive international presence in Europe, the United States, Africa and Asia. In addition, the bank is one of the ten largest banks in the world measured by market capitalization. Barclays is headquartered in London, England.
-
Barclays Downgrades Pfizer (PFE) to Equalweight
-
Notable 52-Week Highs and Lows of the Day 06/27: (ICGN) (CROX) (SAPE) High; (PTIE) (HOGS) (DWA) Low
-
Barclays Maintains an 'Overweight' on Bristol-Myers (BMY); ARISTOTLE Delivers One-Two Punch; Eliquis Poised to be the Market Leader
-
Barclays on U.S. Major Pharmaceuticals: Pipelines Revived? Making Strides in Oncology, Cardiology, and Virology
-
Global Pharmaceuticals: Global Therapeutic Conference 2011: Focus on Real-World Medicine
-
Barclays on U.S. Major Pharmaceuticals: 1Q11 Preview: Restructuring or New Products - Which Is The Lifeline For Pharma?
-
Barclays Maintains an 'Overweight' on Pfizer (PFE); Model Update: Capsugel Sale As Expected
-
Barclays on U.S. Specialty Pharmaceuticals: Mylan Influencing Lipitor Landscape?
-
Barclays Maintains an 'Overweight' on Pfizer (PFE); Q4 Review: Making the Right Moves
-
Barclays on U.S. Major Pharmaceuticals: U.S. Major Pharma 2011 Outlook: A View Beyond the Cliff
-
Barclays Maintains an 'Overweight' on Pfizer (PFE); King Acquisition: Good But Not Great
-
Barclays Maintains an 'Overweight' Rating on Pfizer (PFE); Grange Castle, Ireland Tour: Pfizer Emphasizes the Prevnar Family
-
Barclays Pipeline Update on Pfizer (PFE): Increasing Pressure for Apixaban and Tasocitinib to Perform
-
Barclays Maintains an 'Overweight' on Pfizer (PFE); Pipeline Dimming; Capital Allocation Comes Into Focus
-
Loeb's Third Point Q4 13F Breakdown: Ups Bets In Financials, Exits Large Pharma
-
Notable Analyst Rating Changes 10/19: AXP, NOV, EL, DKS Upgrade; FNM/FRE, ANF, MAT, LUV Downgrade
-
Barclays Resumes Coverage on Pfizer (PFE) with an Overweight
-
David Moenning's Daily State of the Markets: 2/9
-
David Moenning's Daily State of the Markets: 2/2
-
Notable Analyst Rating Changes 2/2: PFE, ESRX, CLX, AKAM Upgraded; F, NYX, ETFC, WU Downgraded
-
Morning Movers 1/26: Barclays plc (BCS) Up After Easing Concerns; Rohm and Haas (ROH) Slammed As Dow Walks
-
Morning Movers 1/23: Wyeth (WYE) Higher On Bid Report; Microsemi (MSCC) Slammed On Results/Guidance
-
Notable Analyst Rating Changes 1/12: CFR, PALM, PFE Upgraded; AA, HOG, MDAS, BNI Downgraded
-
David Moenning's Daily State of the Markets: 10/20
-
Notable Analyst Rating Changes 10/20: KFT, RIG, BBY, PFE, YGE Upgraded; DE, INTC, MET, POZN Downgraded
-
Barclays Capital Upgrades Pfizer (PFE) to Overweight
-
Pre-Open Movers 9/3: Medivation (MDVN) Surges On Pfizer Deal; Corning (GLW) Sinks on Warning
